Welcome to our dedicated page for Adma Biologics news (Ticker: ADMA), a resource for investors and traders seeking the latest updates and insights on Adma Biologics stock.
ADMA Biologics, Inc. (NASDAQ: ADMA) is a U.S.-based, end-to-end commercial biopharmaceutical company focused on specialty plasma-derived biologics and other specialty biologics for immunodeficient patients and individuals at risk for certain infectious diseases. The ADMA news feed on Stock Titan aggregates company-issued updates and market-moving announcements so readers can follow developments affecting the ADMA stock and its underlying business.
In its press releases, ADMA regularly reports on quarterly and annual financial results, including total revenue, GAAP net income, adjusted EBITDA and adjusted net income, as well as updates to its financial guidance. The company also issues news on operational milestones such as U.S. Food and Drug Administration (FDA) approvals for its production processes, progress with its yield enhancement production technology, and expansion of its U.S.-based manufacturing and plasma collection infrastructure.
Investors following ADMA news can expect coverage of commercial trends for its FDA-approved plasma-derived products ASCENIV, BIVIGAM and NABI-HB, including reported demand dynamics, payer coverage discussions, and distribution agreements. The company’s updates also address pipeline progress for SG-001, a pre-clinical hyperimmune globulin targeting Streptococcus pneumoniae, along with commentary on intellectual property, supply chain strategy and capital structure actions such as debt refinancing and share repurchase authorizations.
This news page is useful for tracking how ADMA communicates its financial outlook, operational initiatives and product performance over time. Readers interested in the ADMA stock can use the curated news flow to monitor earnings releases, regulatory and manufacturing updates, and other disclosures that the company furnishes through press releases and related filings.
ADMA (Nasdaq: ADMA) announced a 2026 capital return initiative targeting $200 million, including a $125 million accelerated share repurchase (ASR) with JPMorgan, and plans to complete the ASR within about five months.
The company will initially receive ~6.4 million shares (≈80% of expected ASR shares) based on a $15.57 close on Feb 27, 2026, and retains up to $500 million authorized repurchases.
ADMA (Nasdaq: ADMA) reported record FY2025 results with $510.2M total revenue (+20% YoY), $363M ASCENIV sales (+51% YoY), $160.8M adjusted net income (+35% YoY) and $231.0M adjusted EBITDA (+40% YoY). Management highlighted yield-enhanced production in full commercial operation, a $12M plasma center divestiture pending Q1 2026, ~$88M cash on hand and reiterated 2026–2029 guidance targeting >$1.1B revenue and >$700M adjusted EBITDA in 2029.
Company appointed Terry Kohler as CFO to support capital allocation, working capital execution and continued commercial scaling.
ADMA Biologics (Nasdaq: ADMA) will report its fourth quarter and full year 2025 financial results on February 25, 2026 after market close. Management will host a live conference call and audio webcast at 4:30 p.m. ET to discuss results and company updates.
Participants must register to receive dial-in numbers and a unique PIN; a replay will be archived under Events & Webcasts on the company investor website.
ADMA Biologics (Nasdaq: ADMA) reported preliminary unaudited FY2025 revenue of $510–511 million, year-end cash of ~$88 million, and estimated $40 million of 4Q2025 operating cash flow. The company reiterated FY2025 adjusted EBITDA and adjusted net income guidance and raised FY2026 revenue and adjusted EBITDA targets to $635M and $360M, respectively, with FY2027 revenue and adjusted EBITDA expected at $775M and $455M. ADMA expects 2026 to be its first full year of yield-enhanced production, announced plasma center divestitures for $12M proceeds with long-term supply agreements, and plans an FDA pre-IND submission for SG-001 in 2026. Long-term targets include >$1.1B revenue and >$700M adjusted EBITDA by FY2029.
ADMA Biologics (Nasdaq: ADMA) announced that Adam Grossman, President and CEO, will deliver a podium presentation at the J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 9:45 a.m. PT.
A live audio webcast will be available under Events & Webcasts in the company investor website and an archived webcast will be posted after the event.
ADMA (Nasdaq: ADMA) reported 3Q 2025 revenue $134.2M (+12% YoY), GAAP net income $36.4M, and Adjusted EBITDA $58.7M (+29% YoY). The company received FDA lot release for its first yield‑enhanced production batches, expected to drive gross margin expansion beginning in 4Q 2025 and through 2026. ASCENIV showed record utilization and a retrospective analysis reported infections falling from 2.1 to 0.9 per year (p<0.05). ADMA raised FY2025 revenue guidance to $510M+, FY2026 to $630M+, reaffirmed FY2025 Adjusted EBITDA at $235M, and raised FY2026 Adjusted EBITDA to $355M+. Company cites disciplined capital deployment, ongoing share repurchases, and SG‑001 pipeline upside.
ADMA Biologics (Nasdaq: ADMA) will report third quarter 2025 financial results on November 5, 2025 after U.S. market close.
Management will host a live conference call and audio webcast on November 5, 2025 at 4:30 p.m. ET to discuss financial results and company updates. Participants must register to receive dial-in numbers and a unique PIN; joining ~10 minutes early is recommended. A live webcast will be available for listeners, and an archived replay will be posted under Events & Webcasts on the company investor site: https://ir.admabiologics.com/events-webcasts.
ADMA Biologics (Nasdaq: ADMA) reported strong Q2 2025 financial results with total revenue of $122.0 million, up 14% year-over-year (29% excluding prior year non-recurring item). The company achieved GAAP net income of $34.2 million and Adjusted EBITDA of $50.8 million.
Key developments include initiating commercial-scale manufacturing with an FDA-approved yield enhancement process delivering 20%+ increase in finished IG output, securing a $300 million syndicated debt refinancing led by J.P. Morgan, and expanding operations with a new Boca Raton facility acquisition that could increase cGMP manufacturing space by up to 30%.
ADMA reaffirmed its guidance, projecting FY 2025 revenue over $500 million and FY 2026 revenue of $625+ million. The company expects to reach $1.1+ billion in annual revenue before 2030.
ADMA Biologics (NASDAQ: ADMA), a U.S.-based biopharmaceutical company focused on specialty biologics, has scheduled its second quarter 2025 financial results announcement for August 6, 2025, after market close.
The company will host a conference call and audio webcast at 4:30 p.m. ET on the same day. Participants must pre-register to receive dial-in information and a unique PIN. A replay of the webcast will be available in the investor section of ADMA's website.
ADMA Biologics reported strong Q1 2025 financial results with total revenue of $114.8 million, up 40% year-over-year. The company achieved GAAP Net Income of $26.9 million (51% YoY increase) and Adjusted EBITDA of $47.9 million (81% YoY increase). ADMA received FDA approval for its yield enhancement process, expected to increase production output by 20% from the same plasma volume.
The company increased its guidance for FY 2025 and 2026, projecting total revenues of $500+ million and $625+ million respectively. ADMA authorized a $500 million share repurchase program, representing 8% of current market capitalization. The company's debt reorganization reduced cost of debt capital by 1.1%. ADMA now expects to achieve $1.1 billion in annual revenues before 2030, with anticipated margin expansion.